This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comparative Study

. 2002 Feb;20(2):347.

doi: 10.1097/00004872-200202000-00027.

Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricemia and gout

Evagelos Liberopoulos, Dimitris Christides, Moses Elisaf

PMID: 11821722
DOI: 10.1097/00004872-200202000-00027

Comparative Study

Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricemia and gout

Evagelos Liberopoulos et al. J Hypertens. 2002 Feb.

. 2002 Feb;20(2):347.

doi: 10.1097/00004872-200202000-00027.

Authors

Evagelos Liberopoulos, Dimitris Christides, Moses Elisaf

PMID: 11821722
DOI: 10.1097/00004872-200202000-00027

No abstract available

PubMed Disclaimer

Comment on

Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout.
Würzner G, Gerster JC, Chiolero A, Maillard M, Fallab-Stubi CL, Brunner HR, Burnier M. Würzner G, et al. J Hypertens. 2001 Oct;19(10):1855-60. doi: 10.1097/00004872-200110000-00021. J Hypertens. 2001. PMID: 11593107 Clinical Trial.

Similar articles

Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout.
Würzner G, Gerster JC, Chiolero A, Maillard M, Fallab-Stubi CL, Brunner HR, Burnier M. Würzner G, et al. J Hypertens. 2001 Oct;19(10):1855-60. doi: 10.1097/00004872-200110000-00021. J Hypertens. 2001. PMID: 11593107 Clinical Trial.
Effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia in Chinese population.
Dang A, Zhang Y, Liu G, Chen G, Song W, Wang B. Dang A, et al. J Hum Hypertens. 2006 Jan;20(1):45-50. doi: 10.1038/sj.jhh.1001941. J Hum Hypertens. 2006. PMID: 16281062 Clinical Trial.
Impact of irbesartan, an angiotensin receptor blocker, on uric acid level and oxidative stress in high-risk hypertension patients.
Chida R, Hisauchi I, Toyoda S, Kikuchi M, Komatsu T, Hori Y, Nakahara S, Sakai Y, Inoue T, Taguchi I. Chida R, et al. Hypertens Res. 2015 Nov;38(11):765-9. doi: 10.1038/hr.2015.82. Epub 2015 Jul 16. Hypertens Res. 2015. PMID: 26178150 Clinical Trial.
[GOUT AND HYPERTENSION].
Belovol AN, Knyazkova II, Miroshnykova IA. Belovol AN, et al. Lik Sprava. 2015 Jan-Mar;(1-2):32-8. Lik Sprava. 2015. PMID: 26118024 Review. Russian.
Irbesartan treatment in hypertension.
Brown MJ. Brown MJ. Hosp Med. 1998 Oct;59(10):808-11. Hosp Med. 1998. PMID: 9850301 Review.

See all similar articles

Cited by

EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).
Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Lioté F, McCarthy G, Netter P, Nuki G, Perez-Ruiz F, Pignone A, Pimentão J, Punzi L, Roddy E, Uhlig T, Zimmermann-Gòrska I; EULAR Standing Committee for International Clinical Studies Including Therapeutics. Zhang W, et al. Ann Rheum Dis. 2006 Oct;65(10):1312-24. doi: 10.1136/ard.2006.055269. Epub 2006 May 17. Ann Rheum Dis. 2006. PMID: 16707532 Free PMC article. Review.
Fifteen years of losartan: what have we learned about losartan that can benefit chronic kidney disease patients?
Ripley E, Hirsch A. Ripley E, et al. Int J Nephrol Renovasc Dis. 2010;3:93-8. doi: 10.2147/ijnrd.s7038. Epub 2010 Jun 28. Int J Nephrol Renovasc Dis. 2010. PMID: 21694934 Free PMC article.
Simultaneous electrochemical determination of uric acid and hypoxanthine at a TiO₂/graphene quantum dot-modified electrode.
Ngoc Hoang V, Hoa DTN, Quang Man N, Son LVT, Son LVT, Nguyen VT, Phong LTH, Diem LH, Ly KC, Thang HS, Quang Khieu D. Ngoc Hoang V, et al. Beilstein J Nanotechnol. 2024 Jun 20;15:719-732. doi: 10.3762/bjnano.15.60. eCollection 2024. Beilstein J Nanotechnol. 2024. PMID: 38919168 Free PMC article.
Silky Co₃O₄ nanostructures for the selective and sensitive enzyme free sensing of uric acid.
Chang AS, Tahira A, Chang F, Memon NN, Nafady A, Kasry A, Ibupoto ZH. Chang AS, et al. RSC Adv. 2021 Jan 27;11(9):5156-5162. doi: 10.1039/d0ra10462k. eCollection 2021 Jan 25. RSC Adv. 2021. PMID: 35424461 Free PMC article.
Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease?
Dawson J, Walters M. Dawson J, et al. Br J Clin Pharmacol. 2006 Dec;62(6):633-44. doi: 10.1111/j.1365-2125.2006.02785.x. Br J Clin Pharmacol. 2006. PMID: 21894646 Free PMC article. Review.

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wolters Kluwer
Medical
- MedlinePlus Health Information